We are focused on the bringing of our cell therapy and immunotherapies to patients in need.

HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility ("HemoGenyx"). HemoGenyx is a preclinical-stage biotechnology company focused on the discovery, development and commercialisation of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy.

HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

Our passionate mission

We believe that we can transform patients' lives by delivering breakthrough therapies.
We also believe that good business means healthy people and a better world.

To develop new therapies that are based on breakthrough science
To bring hope to patients with serious or life threatening diseases
To treat life threatening diseases, bringing societal benefit
To realize unique treatment opportunities for patients and value for investors

Our core values are Integrity, Courage and Ingenuity

Integrity means that we are open, honest and genuine. Courage means that we are entrepreneurial, take calculated risks and strive to reach beyond the boundaries of accepted theories. Ingenuity means that we discover, invent and use our discoveries for the benefit of the patients.